Will BMY's EPS growth continue in 2025?

**Bristol-Myers Squibb's (BMY) EPS growth is not expected to continue in 2025.** Here's why:

1. **Recent Performance**: BMY's EPS in the most recent quarter (2024Q4) was $0.04, a significant decline of -95.4% from the same period in the previous year. This indicates a sharp downturn in earnings, which is a red flag for future EPS growth.

2. **Analyst Expectations**: For the upcoming year (2025), no data indicates a positive EPS growth. In fact, the EPS guidance for FY 2025 is set at $6.550-6.850, compared to the consensus EPS estimate of $6.920. This suggests that analysts do not expect a strong rebound in EPS.
3. **Market Trends**: Despite a slight increase in stock price and outperformance in the market, as seen in the recent trading session, the overall market conditions and company-specific factors do not indicate a strong EPS growth trajectory for 2025.
4. **Strategic Initiatives**: While BMY has been making strategic moves, such as planned acquisitions and focusing on cost savings, these initiatives may not immediately translate to EPS growth due to the nature of pharmaceutical development and regulatory processes.

In conclusion, given the current EPS figures, analyst expectations, and market trends, BMY's EPS growth is not anticipated to continue in 2025. The company's performance will likely be influenced by its strategic initiatives and market conditions, which may provide some support but do not guarantee a swift recovery or growth in EPS.